A comprehensive view of Moderna Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Fitch: Covid-19 vaccine sales saw strong start to 2022, with Pfizer and Moderna posting stronger-than-expected Q1 sales; 2022 sales could be comparable to significant 2021 numbers, but estimates for 2023 should see more pronounced decrease in market size

Moderna investing €500M in new laboratory in Spain to produce mRNA vaccines reports Spanish prime minister Pedro Sanchez; Moderna currently partnering with Laboratorios Farmaceuticos Rovi SA in Madrid to increase Rovi’s mRNA medicine capacity

Moderna building US$1.35B research, manufacturing center in Britain to develop vaccines for new COVID-19 variants, other respiratory diseases; plant to open in 2025 on site to be determined soon, have capacity of 250 million doses annually

Suburban Walgreens pharmacies will begin offering Pfizer, Moderna vaccines to children ages 3 and older starting next week; CVS will also begin administering vaccines to children 18 months through 4 years old at its MinuteClinic locations

FDA grants emergency use authorization for Pfizer-BioNTech’s and Moderna’s COVID-19 vaccines for children ages 6 months to 4 years-old; 2.5 million doses of Pfizer vaccine ordered, 1.3 million doses of Moderna vaccine ordered

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count